Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modi-1 Moditope vaccine in advanced solid tumors
NCT05329532Phase 2Recruiting
- Sponsor
- Scancell
- Start
- Apr 2022
- Primary completion
- Jul 2026
- Modality
- Split/Subunit Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Modi-1 in triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (HNSCC), high grade serous ovarian carcinoma (HGSC), renal cell carcinoma (RCC), sponsored by Scancell. Started Apr 2022; status: recruiting.
02
Drugs
Modi-1
03
Conditions
triple-negative breast cancer (TNBC)squamous cell carcinoma of the head and neck (HNSCC)high grade serous ovarian carcinoma (HGSC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05329532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329532.